Delivery Order SPE2DB20D7061-SPE2DB25FSNA7
- Not listed
- The Defense Logistics Agency awarded a $1,002.95 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Pimecrolimus 1% Cream in 30-gram units. This firm fixed-price delivery order, with an ultimate completion date of September 15, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Pimecrolimus 1% Cream in a 30-gram quantity, valued at $20,510.86. This delivery order, issued on September 11, 2025, represents a firm fixed-price contract with an ultimate completion date of September 12, 2025. The contract carries no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp will perform the work at its corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 2, 2025, for the supply of Pimecrolimus 1% Cream in 30-gram units, with a ceiling value of $1,484.50. This firm fixed-price delivery order, with an ultimate completion date of July 3, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation....
- The Defense Logistics Agency (DLA) awarded a $2,458.75 delivery order to AmerisourceBergen Drug Corp for Pimecrolimus 1% Cream in 100-gram units, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation, performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pimecrolimus 1% Cream in a 60-gram container, valued at $1,075.73 with a firm fixed price contract type. The delivery order, issued on June 13, 2025, is scheduled for ultimate completion by June 16, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award represents a non-set-aside, competitively awarded transaction through the federal procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,887.66 to AmerisourceBergen Drug Corp for the supply of Pimecrolimus 1% Cream in 30-gram units. This firm fixed price, non-competitive delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025. The pharmaceutical product will be delivered to the prime contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,031.34 to AmerisourceBergen Drug Corp for Pimecrolimus 1% Cream in 100-gram quantities. This non-competitive delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a firm fixed-price procurement executed under a child contract mechanism. The contractor, headquartered in Conshohocken, Pennsylvania, performed this order from its corporate office location. Pimecrolimus is a...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Pimecrolimus 1% Cream in 100-gram units. This contract, valued at $3,265.16, represents a firm fixed-price delivery order with an ultimate completion date of August 11, 2025. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,138.56 for Pimecrolimus 1% Cream 30GM, a topical immunosuppressant medication commonly used to treat inflammatory skin conditions. Awarded on August 28, 2025, with a completion date of August 29, 2025, this firm fixed-price delivery order represents a competitive award with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- This is a $1,139.60 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide 100 gram tubes of Pimecrolimus 1% cream. The contract has an ultimate completion date of July 3, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global...
- SPE2DB20D7061Indefinite Delivery Contract
- SPE2DB20D7061-SPE2DB25FSNA7Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 1, 2025, for the supply of Pimecrolimus 1% Cream in 30-gram units, with a ceiling value of $10,804.84 and an ultimate completion date of May 2, 2025. This is a firm fixed-price delivery order under a non-set-aside competitive procurement, with performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical supply action supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables comprehensive global pharmaceutical support for military healthcare programs. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp regularly fulfills medical supply requirements for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through open competition, demonstrating consistent capability to meet federal procurement standards across a broad therapeutic product portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.8k | 5/1/25 |